GlassScriptPhysician profile
H James Wedner
NPI 1386661809
$419,630.76
in general payments reported to CMS, 2019-2025
31 companies · $59K in 2025
The $59K reported for 2025 was more than what 97% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $31K · 2021: $29K · 2022: $54K · 2023: $66K · 2024: $87K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Honoraria: $53K · Consulting Fee: $43K · Travel and Lodging: $20K · Food and Beverage: $5,367 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,999.70 |
| Honoraria | $53,286.75 |
| Consulting Fee | $42,672.79 |
| Travel and Lodging | $19,637.53 |
| Food and Beverage | $5,367.43 |
| Education | $136.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $75,778.34 | 2022-2025 | Ayvakit |
| Genentech USA, INC. | $74,616.43 | 2019-2025 | Xolair |
| Csl Behring | $59,407.39 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $46,799.08 | 2020-2025 | Takhzyro, Cinryze |
| Ionis Pharmaceuticals, INC. | $33,617.79 | 2025 | Dawnzera, Donidalorsen |
| Glaxosmithkline, LLC. | $30,086.06 | 2020-2025 | Nucala |
| Grifols USA, LLC | $20,139.81 | 2020-2025 | Xembify, Gamunex-C |
| Biocryst US Sales Co., LLC | $19,393.05 | 2021-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $16,411.21 | 2019-2023 | Breztri |
| Regeneron Healthcare Solutions, INC. | $12,068.51 | 2019-2024 | Dupixent |
| Biocryst Pharmaceuticals, INC. | $11,368.96 | 2019-2024 | Orladeyo |
| Shire North American Group INC | $5,540.33 | 2019 | |
| Pharming Healthcare, INC. | $4,983.74 | 2019-2024 | Ruconest |
| Astrazeneca Uk Limited | $2,955.70 | 2019-2023 | Fasenra |
| Genzyme Corporation | $2,748.80 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $1,330.00 | 2025 | |
| Grifols Shared Services North America, INC. | $950.00 | 2025 | Xembify |
| Cycle Pharmaceuticals INC | $757.50 | 2021 | |
| Biomarin Pharmaceutical INC. | $314.73 | 2021-2024 | |
| Galderma Laboratories, L.P. | $116.64 | 2025 | Nemluvio |
| Pfizer INC. | $66.89 | 2022-2025 | |
| Genentech, INC. | $62.64 | 2023 | Xolair |
| Bio Products Laboratory USA, INC. | $56.51 | 2023 | Coagadex, Gammaplex |
| Novartis Pharmaceuticals Corporation | $44.19 | 2019 | |
| Mylan Specialty L.P. | $15.40 | 2023 | Yupelri |
| Organon LLC | $1.06 | 2025 | Vtama |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H James Wedner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.